sibeprenlimab-szsi (Voyxact)
sibeprenlimab-szsi is an FDA-licensed reference biologic from Otsuka Pharmaceutical Company, Ltd.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Voyxact sibeprenlimab-szsi
Otsuka Pharmaceutical Company, Ltd.
- Approved
- Nov 25, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for sibeprenlimab-szsi, in chronological order.
Reference approval
Approval date of the reference sibeprenlimab-szsi product.
6 mo ago
Frequently asked questions
Are there biosimilars approved for sibeprenlimab-szsi (Voyxact)?
No 351(k) biosimilars or interchangeable biosimilars referencing sibeprenlimab-szsi are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.